Efficacy of convalescent plasma therapy in severe COVID-19 patients

Basit Öğe Kaydı
dc.contributor.authorCizmecioglu, Hilal Akay
dc.contributor.authorGoktepe, Mevlut Hakan
dc.contributor.authorDemircioglu, Sinan
dc.contributor.authorTekinalp, Atakan
dc.contributor.authorCizmecioglu, Ahmet
dc.contributor.authorTuna, Ali Kursat
dc.contributor.authorOzer, Huseyin
dc.date.accessioned2024-02-23T14:16:28Z
dc.date.available2024-02-23T14:16:28Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractIntroduction: The use of convalescent plasma (CP) transfusions is very valuable in the current COVID-19 outbreak, given that there are no specific preventive and therapeutic options. Materials and methods: 50 patients with severe COVID-19 disease treated with convalescent plasma transfusion were included in the study. The efficacy of CP and in which situations it was effective were investigated. Conclusion: 80 % of the patients recovered, and 20 % died in our study. The mean age of the patients who died was found to be higher than the patients who recovered. CRP, ferritin, D-dimer, neutrophil, MPV, and NLR counts were found to be higher, and lymphocyte and platelet counts were lower in the deceased group after CP. It was determined that patients who received CP within the first five days were hospitalized for a shorter period. Discussion: Administration of CP transfusion within the first five days in severe COVID-19 patients has been shown to reduce hospital stay length.en_US
dc.identifier.doi10.1016/j.transci.2021.103158
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue4en_US
dc.identifier.pmid33994106en_US
dc.identifier.scopus2-s2.0-85105791521en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103158
dc.identifier.urihttps://hdl.handle.net/20.500.12452/12656
dc.identifier.volume60en_US
dc.identifier.wosWOS:000709808800008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion And Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConvalescent Plasmaen_US
dc.subjectCovid-19en_US
dc.subjectEarly Transfusionen_US
dc.subjectSars-Cov-2en_US
dc.titleEfficacy of convalescent plasma therapy in severe COVID-19 patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu